|
시장보고서
상품코드
1779102
세계의 식물 유래 원료의약품(API) 시장 - 시장 규모, 점유율, 동향, 기회, 예측, 분자 유형별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)Plant Based API Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Molecule Type, By End User, By Region & Competition, 2020-2030F |
||||||
식물 유래 원료의약품(API) 세계 시장 규모는 2024년 314억 달러로 평가되었고, 2030년까지 445억 2,000만 달러에 이르고, CAGR은 5.95%를 나타낼 전망입니다.
세계의 식물 유래 원료의약품(API) 시장은 기술 혁신, 소비자 주도형 헬스케어 수요 증가, 만성 질환의 이환율의 상승, 예방 의료에 대한 주목 증가 등 주요 촉진요인에 추진되어, 대폭적인 성장을 이루고 있습니다. 이에 이르기까지 식물 유래 원료의약품(API) 제품은 개인의 건강 관리에 필수적인 도구가 되고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 314억 달러 |
| 시장 규모 : 2030년 | 445억 2,000만 달러 |
| CAGR 2025-2030년 | 5.95% |
| 급성장 부문 | 의약품 |
| 최대 시장 | 북미 |
진단 기술의 진보, 소비자의 건강 의식의 증가, 보다 저렴한 가격으로 이용하기 쉽고 개별화된 건강 솔루션에의 전환에 힘입어 시장의 성장 궤적은 여전히 견고합니다. 이에 따라 시장은 계속 확대될 것으로 예측됩니다. 규제 당국의 지원과 진단제의 지속적인 혁신은 시장의 잠재력을 더욱 높여주고 식물 유래 원료의약품(API) 분야는 의료 및 진단제 업계의 이해관계자에게 유리한 기회로 자리매김하고 있습니다.
천연 및 유기 제품에 대한 수요 증가
규제의 복잡성과 통일 기준의 부족
가장 임박한 과제 중 하나는 세계 시장 전체에서 식물 유래 원료의약품(API)에 관한 표준화되고 조화로운 규제 프레임워크가 부족하다는 점입니다.
이러한 단편적인 규제환경은 투자자와 개발자에게 불확실성을 가져오고, 연구개발과 국제적인 사업전개를 늦추고 있습니다.
식물 의약품을 주류 의약품 개발에 통합
이 동향은 의약품 혁신의 패러다임 이동을 의미하며, 자연 유래의 원약은 더 이상 주변적인 것이 아니라 현대적인 치료제 중에서 전략적으로 자리매김하게 되어 왔습니다.
Global Plant Based API market was valued at USD 31.40 Billion in 2024 and is expected to reach USD 44.52 Billion by 2030 with a CAGR of 5.95%. The global Plant Based API market is undergoing substantial growth, fueled by key drivers such as technological innovation, increasing demand for consumer-driven healthcare, the rising incidence of chronic diseases, and a growing focus on preventive care. Plant Based API products ranging from blood tests and pregnancy kits to glucose monitors and allergy testing solutions are progressively becoming integral tools for individuals managing their own health. These devices enable users to monitor a variety of health parameters independently, eliminating the need for clinical visits and empowering consumers to take control of their health.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 31.40 Billion |
| Market Size 2030 | USD 44.52 Billion |
| CAGR 2025-2030 | 5.95% |
| Fastest Growing Segment | Pharmaceuticals |
| Largest Market | North America |
The market's growth trajectory remains robust, underpinned by advancements in diagnostic technologies, heightened consumer health consciousness, and a shift toward more affordable, accessible, and personalized health solutions. As these Plant Based API products become increasingly central to health management strategies, the market is expected to continue expanding. Regulatory support and ongoing innovations in diagnostics further enhance the market's potential, positioning the Plant Based API segment as a lucrative opportunity for stakeholders in the healthcare and diagnostics industries.
Key Market Drivers
Rising Demand for Natural and Organic Products
The surge in global demand for natural and organic products is a powerful and influential factor driving the growth of the plant-based active pharmaceutical ingredient (API) market. Sales of natural and organic products have demonstrated consistent upward momentum, with select categories showing exceptional performance. Notably, natural organic meat, fish, and poultry recorded a 13.1% year-over-year growth in 2024, while the organic dairy segment posted a 9.8% increase during the same period. These figures reflect a significant shift in consumer purchasing behavior, underscoring a strong preference for clean-label, sustainably sourced food products within high-consumption categories. Today's consumers are increasingly informed and health conscious. There is a marked preference for products perceived as "clean," chemical-free, and closer to nature. As a result, medications and supplements that are plant-based are seen as gentler on the body, safer for long-term use, and less likely to cause side effects. This perception fuels growing patient and consumer interest in natural-origin pharmaceuticals, creating strong demand for APIs derived from botanical sources. A recent study indicates that 80% of millennials factor in health benefits when making food choices, compared to 64% of baby boomers (individuals born between 1946 and 1964). Importantly, millennials evaluate health not only through the lens of physical wellness but also consider emotional and social well-being as integral to their dietary decisions highlighting a broader, more holistic approach to nutrition among this demographic. The global healthcare narrative is gradually moving away from reactive treatment toward preventive care and holistic wellness. Plant-based products, often associated with traditional healing systems and holistic health, are viewed as ideal for preventive care. Consequently, pharmaceutical companies are under increasing pressure to develop formulations that align with wellness trends, further pushing demand for plant-based APIs in both prescription and over-the-counter segments.
Key Market Challenges
Regulatory Complexity and Lack of Harmonized Standards
One of the most pressing challenges is the lack of standardized and harmonized regulatory frameworks for plant-based APIs across global markets.
Plant-based APIs are often categorized differently across regions ranging from herbal medicines to dietary supplements or even traditional remedies. This inconsistency complicates product registration, labeling, and market entry, particularly in regulated markets such as the U.S., EU, and Japan. Unlike synthetic APIs, which follow well-defined approval pathways, plant-based APIs require complex documentation of botanical origin, bioactive compound consistency, and clinical efficacy, which can vary depending on the source and preparation method. Complying with multiple sets of regulatory standards increases time-to-market and operational costs, particularly for SMEs and regional manufacturers attempting to scale globally.
This fragmented regulatory environment creates uncertainty for investors and developers, slowing R&D and international expansion.
Key Market Trends
Integration of Phytopharmaceuticals into Mainstream Drug Development
A significant trend reshaping the plant-based API market is the growing integration of phytopharmaceuticals into conventional drug pipelines. Historically, plant-based compounds were largely confined to traditional medicine or nutraceutical applications. However, this is changing as pharmaceutical companies recognize their potential for targeted therapeutic action with fewer side effects.
A rising number of plant-derived compounds are undergoing clinical trials, validating their efficacy for chronic and lifestyle-related diseases such as diabetes, cardiovascular disorders, cancer, and neurodegenerative conditions. Major pharmaceutical firms are partnering with biotech startups and research institutes to co-develop plant-based drugs leveraging natural product libraries for lead discovery and screening. Advances in extraction, purification, and delivery systems have allowed for the development of proprietary formulations, making plant-based APIs commercially attractive due to stronger IP protections and differentiated value propositions.
This trend signifies a paradigm shift in pharma innovation, where nature-based APIs are no longer peripheral but are being strategically positioned within modern therapeutics.
In this report, the Global Plant Based API Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Plant Based API Market.
Global Plant Based API market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: